TTC31: A Promising Drug Target and Biomarker for Tetratricopeptide Repeat-Containing Proteins

Target Name: TTC31

NCBI ID: G64427

TTC31

TTC31: A Promising Drug Target and Biomarker for Tetratricopeptide Repeat-Containing Proteins

Abstract:

Tetratricopeptide (TTP) repeat proteins are a diverse family of non-coding RNAs that have been implicated in various cellular processes. One of the most well-studied TTP repeat proteins is TTC31, which is a 21-kDa protein that is expressed in various tissues and tissues and diseases. Although the primary function of TTC31 is not well understood, recent studies have suggested that it may be a promising drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. In this article, we will summarize the current understanding of TTC31, its potential drug target properties, and its potential as a biomarker for disease diagnosis and treatment.

Introduction:

Tetratricopeptide (TTP) repeat proteins are a family of non-coding RNAs that have been identified in various species, including humans. These proteins are characterized by the repeated sequence of four amino acids, which is usually terminated by a poly(A) tail. Despite the repetitive nature of their sequence, TTP repeat proteins have unique properties that have led to their interest in various cellular processes. One of the most well-studied TTP repeat proteins is TTC31, which is a 21-kDa protein that is expressed in various tissues and diseases.

Function and Localization:

TTC31 is a protein that is primarily localized to the endoplasmic reticulum (ER) and cytoplasm. It is highly expressed in the brain and is also found in other tissues, including muscle, heart, and kidney. TTC31 is predominantly monomeric and has a calculated molecular mass of 42 kDa. It is characterized by a unique 21-kDa protein that consists of a single coding gene.

Structure and Mechanism:

The primary function of TTC31 is not well understood, but recent studies have suggested that it may be involved in various cellular processes. TTC31 has a distinct N-terminus that is involved in protein-protein interactions (PPIs) and a C-terminus that is involved in intracellular signaling pathways. The middle region of TTC31 contains a repeated sequence of four amino acids (TTP repeat sequence), which is terminated by a poly(A) tail.

Drug Target Potential:

TTC31 has been identified as a potential drug target due to its unique structure and function. The TTP repeats and its involvement in PPIs make it a promising target for small molecules. Additionally, TTC31 has been shown to interact with various signaling pathways, including the T cell signaling pathway, which suggests that it may be involved in immune regulation. Therefore, small molecules that can modulate the activity of TTC31 and its downstream targets may be useful for therapeutic applications.

Biomarker Potential:

TTC31 has the potential to serve as a biomarker for various diseases due to its unique expression patterns and cellular localization. The brain is a well-established biomarker for many diseases, including neurodegenerative disorders. Therefore, the expression of TTC31 in the brain may be a Useful biomarker for the diagnosis and treatment of these disorders. Additionally, TTC31 has been shown to be expressed in various tissues and diseases, including cancer, which suggests that it may be a useful biomarker for cancer diagnosis and treatment.

Conclusion:

TTC31 is a unique protein that has the potential to serve as a drug target and biomarker for various diseases. Its unique structure and function, as well as its expression patterns in various tissues and diseases, make it an attractive target for small molecules. Further studies are needed to fully understand the function of TTC31 and its potential as a drug

Protein Name: Tetratricopeptide Repeat Domain 31

The "TTC31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets